Sage is handling the initial data processing and cleaning for the consortium, while MSKCC is providing infrastructure for hosting the data.
Researchers from Memorial Sloan Kettering found that many cancer patients harbor germline variants, sometimes in unexpected genes, that could inform their care.
The initial phase of GENIE, which stands for Genomics, Evidence, Neoplasia, Information, Exchange, involves seven founding members and two informatics partners.
MSK will collect the samples and Illumina will analyze them for ctDNA using its sequencing technology.
A team led by Memorial Sloan Kettering researchers showed advantages of the basket trial design in identifying precision treatment leads for rare cancer populations.
So far, results from the MSK-IMPACT test have been reported for more than 4,500 patients.
Teams tracked immune cell infiltration, PD-L1 expression, and more in tumors from BRCA1/2-mutated ovarian cancers or mutation-rich endometrial cancer subtypes.
The Broad will partner with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center on a large tumor sequencing study.
The results offer hints at future applications of the platform for use in pharmaceutical partnerships and for clinical diagnostics.
Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.